Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
|
By LabMedica International staff writers Posted on 31 Jul 2018 |

Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Carolina Liquid Chemistries (Greensboro, NC, USA) promoted its EasyRA high-speed benchtop analyzer, its family of clinical chemistry analyzers, CLC800, CLC1600, CLC6410, and extensive menu of reagents at the 70th annual AACC Scientific Meeting & Clinical Lab Expo held from July 31 – August 2. The company also introduced the Maglumi 2000 immunoassay analyzer at the event held in Chicago, USA.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read moreBlood-Based Gene Expression Test Detects Early Pancreatic Cancer
Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more





 Assay.jpg)



